ROIVANT SCIENCES LTD. Foreign Currency Transaction Loss, before Tax
ROIVANT SCIENCES LTD. (ROIV) reported Foreign Currency Transaction Loss, before Tax of $7.10 million for the 9-month period ending 2025-12-31, per its 10-Q filed 2026-02-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:ForeignCurrencyTransactionLossBeforeTax · last filed 2026-08-06
- ROIVANT SCIENCES LTD. foreign currency transaction loss, before tax for the quarter ending 2025-12-31 was $600.00K.
- ROIVANT SCIENCES LTD. foreign currency transaction loss, before tax for the quarter ending 2025-09-30 was -$300.00K.
- ROIVANT SCIENCES LTD. foreign currency transaction loss, before tax for the quarter ending 2025-06-30 was $6.80M.
- ROIVANT SCIENCES LTD. foreign currency transaction loss, before tax for the quarter ending 2024-12-31 was $0.00.
| Period end | Foreign Currency Transaction Loss, before Tax 3 month | Foreign Currency Transaction Loss, before Tax 6 month | Foreign Currency Transaction Loss, before Tax 9 month |
|---|---|---|---|
| 2025-12-31 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $300.00K derived: sum of 2 quarters · filed 2026-02-06 | $7.10M 10-Q · filed 2026-02-06 |
| 2025-09-30 | -$300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $6.50M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $6.80M 10-Q · filed 2026-08-06 | ||
| 2024-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $0.00 10-Q · filed 2026-02-06 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |